Skip main navigation
Close Drawer MenuOpen Drawer Menu

The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
Back to table of contents
Full Access

The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease

Published Online:1 Apr 2006https://doi.org/10.1176/jnp.9.4.594

Abstract

This pilot study investigated effectiveness and tolerability of risperidone for the treatment of psychosis and agitation in 9 inpatients with Parkinson's disease and dementia. Investigators found risperidone to be effective and safe, without worsening extrapyramidal symptoms or further impairing cognition.